Bio-Techne shares jumped 6.5% to close at $55.64 following investor optimism over potential drug-pricing agreements, despite a 22.2% decline year-to-date. The stock's performance aligns with broader market reactions to new initiatives from the Trump administration aimed at lowering prescription drug costs. Meanwhile, Avantor continues to struggle, with its stock down 41.1% this year after RBC Capital Markets lowered its price target.
“Bio-Techne · shares jumped · 5.3% · in the afternoon session”
“Trump administration · is advancing · Most Favored Nation initiative · to lower prescription drug costs”
“Pfizer · entered into an agreement · to sell medications through Medicaid · at reduced prices”
“Bio-Techne · shares closed · $55.64 · up 6.5% from previous close”
“Bio-Techne · has had · 19 moves greater than 5% · over the last year”
“Bio-Techne · reported · 3% organic growth · for the fourth quarter”
“Bio-Techne · is down · 22.2% · since the beginning of the year”
“Bio-Techne · is trading · 30.4% below its 52-week high · of $79.93 from September 2024”
“Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago · would now be looking at · an investment worth $898.24”
“a number of stocks · jumped · in the afternoon session · after reports revealed a potential drug-pricing agreement”
“the Trump administration · is advancing · its “Most Favored Nation” initiative · which aims to lower prescription drug costs for Americans”
“Pfizer · has reportedly entered into · an agreement to voluntarily sell its medications through Medicaid · at these reduced prices”
